Jan Spacek
Overview
Explore the profile of Jan Spacek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krizova L, Benesova I, Zemanova P, Spacek J, Strizova Z, Humlova Z, et al.
J Cancer Res Clin Oncol
. 2024 Feb;
150(2):99.
PMID: 38383923
Purpose: Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used biomarkers, such as PD-L1, MSI, or TMB,...
2.
Bielcikova Z, Werner L, Stursa J, Cerny V, Krizova L, Spacek J, et al.
Ther Adv Med Oncol
. 2023 Oct;
15:17588359231197957.
PMID: 37786538
Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I,...
3.
Kolar V, Chmelova E, Bilkova M, Borovec J, Carreira B, Cerny M, et al.
Sci Total Environ
. 2023 Jul;
900:165803.
PMID: 37499824
Deposits of fly ash and other coal combustion wastes are common remnants of the energy industry. Despite their environmental risks from heavy metals and trace elements, they have been revealed...
4.
Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S, et al.
EClinicalMedicine
. 2023 Apr;
57:101873.
PMID: 37064512
Background: Mitochondria present an emerging target for cancer treatment. We have investigated the effect of mitochondrially targeted tamoxifen (MitoTam), a first-in-class anti-cancer agent, in patients with solid metastatic tumours. Methods:...
5.
Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee J, et al.
Cancers (Basel)
. 2023 Jan;
15(2).
PMID: 36672367
Background: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international...
6.
Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139506
BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I−III colon cancer (CC) in the Asian population. These patients were originally included in an...
7.
Spacek J, Benner S
Astrobiology
. 2022 Jul;
22(10):1255-1263.
PMID: 35796703
Before the first humans depart for Mars in the next decade, hundreds of tons of martian water-ice must be harvested to produce propellant for the return vehicle, a process known...
8.
Nguyen L, Macaluso N, Pizzano B, Cash M, Spacek J, Karasek J, et al.
EBioMedicine
. 2022 Mar;
77:103926.
PMID: 35290826
Background: Current SARS-CoV-2 detection platforms lack the ability to differentiate among variants of concern (VOCs) in an efficient manner. CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated) based detection systems have...
9.
Spacek J, Vocka M, Zavadova E, Konopasek B, Petruzelka L
Immunotherapy
. 2021 Nov;
14(1):31-40.
PMID: 34784798
To evaluate the effect of pleuran (β-glucan from ) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Antitumor cellular...
10.
Nguyen L, Macaluso N, Pizzano B, Cash M, Spacek J, Karasek J, et al.
medRxiv
. 2021 Oct;
PMID: 34704101
Current SARS-CoV-2 detection platforms lack the ability to differentiate among variants of concern (VOCs) in an efficient manner. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has the potential to transform...